Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
22 February 2021Website:
http://www.alumis.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 05 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
What type of business is Alumis Common Stock?
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
What sector is Alumis Common Stock in?
Alumis Common Stock is in the Healthcare sector
What industry is Alumis Common Stock in?
Alumis Common Stock is in the Biotechnology industry
What country is Alumis Common Stock from?
Alumis Common Stock is headquartered in United States
When did Alumis Common Stock go public?
Alumis Common Stock initial public offering (IPO) was on 22 February 2021
What is Alumis Common Stock website?
https://www.alumis.com
Is Alumis Common Stock in the S&P 500?
No, Alumis Common Stock is not included in the S&P 500 index
Is Alumis Common Stock in the NASDAQ 100?
No, Alumis Common Stock is not included in the NASDAQ 100 index
Is Alumis Common Stock in the Dow Jones?
No, Alumis Common Stock is not included in the Dow Jones index
When does Alumis Common Stock report earnings?
Next earnings report date is not announced yet